Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
August 27, 2020 at 04:27 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 564.828 million compared to CNY 689.240 million a year ago. Operating income was CNY 161.686 million compared to CNY 70.266 million a year ago. Net income was CNY 138.553 million compared to CNY 63.034 million a year ago. Basic earnings per share from continuing operations was CNY 0.1575 compared to CNY 0.0716 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.